Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
Artículo en Inglés | MEDLINE | ID: mdl-24765877

RESUMEN

OBJECTIVES: In this multicenter survey, we assessed the impact of sensitization to cypress in atopic patients in Italy and determined whether cypress pollen concentration changed over time. METHODS: Allergists were required to collect the results of 100-200 consecutive skin prick tests (SPTs) performed during 2012. Seasonal symptoms were also recorded, as were airborne cypress pollen concentrations (data from the Italian Aerobiology Association) in 1998-2000 and 2010-2012. RESULTS: We examined 2258 atopic outpatients (56% females; age, 2-84 years) sensitized to at least 1 of the aeroallergens tested (Dermatophagoides species, grass, pellitory, olive, cypress, birch, Alternaria tenuis, and dog and cat dander). We found that 62.9%, 16.1%, and 32.7% of patients living in central, northern, and southern Italy, respectively, were sensitized to cypress (P < .0001). The cypress pollen concentration peak was delayed from February to March in 1998-2000 and 2010-2012 in all 3 regions, with a shift in pollination towards spring. Patients who were monosensitized to cypress reported mainly rhinitis (90.7%-97.6%) and conjunctivitis (38.1%-100%). In polysensitized patients, the prevalence of rhinitis, conjunctivitis, and asthma increased progressively (P < .0001) from southern to northern Italy. The same trend was observed for the prevalence of reported winter symptoms typical of cypress allergy (28%-65%). CONCLUSIONS: Today, cypress pollen is the most frequent sensitizing aeroallergen (assessed by SPT) in several areas of central Italy. Variations in the timing of the cypress pollination period may have favored this increased sensitization. Rhinitis and conjunctivitis are the predominant symptoms. The clinical impact of this allergy was poor in southern Italy and increased in central areas before reaching its peak in northern regions.


Asunto(s)
Alérgenos/inmunología , Cupressus/inmunología , Hipersensibilidad Inmediata/epidemiología , Hipersensibilidad Inmediata/inmunología , Hipersensibilidad/epidemiología , Hipersensibilidad/inmunología , Polen/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Adulto Joven
4.
Mol Psychiatry ; 19(4): 433-43, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24535456

RESUMEN

Stress and glucocorticoids alter glutamatergic transmission, and the outcome of stress may range from plasticity enhancing effects to noxious, maladaptive changes. We have previously demonstrated that acute stress rapidly increases glutamate release in prefrontal and frontal cortex via glucocorticoid receptor and accumulation of presynaptic SNARE complex. Here we compared the ex vivo effects of acute stress on glutamate release with those of in vitro application of corticosterone, to analyze whether acute effect of stress on glutamatergic transmission is mediated by local synaptic action of corticosterone. We found that acute stress increases both the readily releasable pool (RRP) of vesicles and depolarization-evoked glutamate release, while application in vitro of corticosterone rapidly increases the RRP, an effect dependent on synaptic receptors for the hormone, but does not induce glutamate release for up to 20 min. These findings indicate that corticosterone mediates the enhancement of glutamate release induced by acute stress, and the rapid non-genomic action of the hormone is necessary but not sufficient for this effect.


Asunto(s)
Corticosterona/metabolismo , Lóbulo Frontal/patología , Neuronas/patología , Terminales Presinápticos/metabolismo , Estrés Psicológico/patología , Análisis de Varianza , Animales , Ácido Aspártico/metabolismo , Corticosterona/farmacología , Relación Dosis-Respuesta a Droga , Electrochoque/efectos adversos , Potenciales Postsinápticos Excitadores/efectos de los fármacos , Técnicas In Vitro , Masculino , Neuronas/metabolismo , Terminales Presinápticos/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Estrés Psicológico/etiología , Sinapsinas/metabolismo , Vesículas Sinápticas/efectos de los fármacos , Vesículas Sinápticas/metabolismo , Sinaptosomas/metabolismo , Tritio/farmacocinética
5.
J. investig. allergol. clin. immunol ; 24(1): 23-28, ene.-feb. 2014. tab, ilus
Artículo en Inglés | IBECS | ID: ibc-119150

RESUMEN

Objectives: In this multicenter survey, we assessed the impact of sensitization to cypress in atopic patients in Italy and determined whether cypress pollen concentration changed over time. Methods: Allergists were required to collect the results of 100-200 consecutive skin prick tests (SPTs) performed during 2012. Seasonal symptoms were also recorded, as were airborne cypress pollen concentrations (data from the Italian Aerobiology Association) in 1998- 2000 and 2010-2012. Results: We examined 2258 atopic outpatients (56% females; age, 2-84 years) sensitized to at least 1 of the aeroallergens tested (Dermatophagoides species, grass, pellitory, olive, cypress, birch, Alternaria tenuis, and dog and cat dander). We found that 62.9%, 16.1%, and 32.7% of patients living in central, northern, and southern Italy, respectively, were sensitized to cypress (P<.0001). The cypress pollen concentration peak was delayed from February to March in 1998-2000 and 2010-2012 in all 3 regions, with a shift in pollination towards spring. Patients who were monosensitized to cypress reported mainly rhinitis (90.7%-97.6%) and conjunctivitis (38.1%-100%). In polysensitized patients, the prevalence of rhinitis, conjunctivitis, and asthma increased progressively (P<.0001) from southern to northern Italy. The same trend was observed for the prevalence of reported winter symptoms typical of cypress allergy (28%-65%). Conclusions: Today, cypress pollen is the most frequent sensitizing aeroallergen (assessed by SPT) in several areas of central Italy. Variations in the timing of the cypress pollination period may have favored this increased sensitization. Rhinitis and conjunctivitis are the predominant symptoms. The clinical impact of this allergy was poor in southern Italy and increased in central areas before reaching its peak in northern regions (AU)


Antecedentes: Se trata de una encuesta multicéntrica realizada en Italia para evaluar el impacto de la sensibilización a polen de ciprés en sujetos atópicos y establecer si la concentración de este polen en el aire ha cambiado a lo largo del tiempo. Métodos: El estudio fue realizado por alergólogos que recopilaron 100-200 sujetos consecutivos con pruebas cutáneas positivas (Prick) realizadas en 2012. Se recogieron los síntomas estacionales, junto con la concentración de polen de ciprés (obtenida por la asociación italiana de aerobiología) en 1998-2000 y 2010-2012. Resultados: En cuanto a los resultados obtenidos fueron examinados 2258 pacientes atópicos (56% mujeres; edad 2-84), sensibilizados frente al menos uno de los aeroalérgenos testados (Dermatophagoides, gramíneas, parietaria, olivo, cipres, abedul, Alternaria tenuis y epitelio de gato). El 62.9%, 16.1% y 32.7% de los pacientes que vivían en el centro, norte y sur de Italia, respectivamente, mostraron sensibilización a polen de ciprés (p<0.0001). Observamos un pico de concentración de polen de ciprés de febrero a marzo en los años 1998-2000 y 2010-2012, en todas las áreas. Los pacientes monosensibilizados a ciprés mostraron de forma prevalente rinitis (90.7-97.6%) y conjuntivitis (38.1-100%). La prevalencia de rinitis, conjuntivitis y asma se incrementa progresivamente (p<0.0001) del sur hacia el norte de Italia en los sujetos polisensibilizados. La misma tendencia se observó en los síntomas invernales típicos de la alergia al ciprés. Conclusiones: En conclusión, actualmente el polen de ciprés es el aeroalérgeno sensibilizante más frecuente (según resultados de prueba cutánea) en varias áreas de Italia central. Las variaciones del periodo de polinización pueden favorecer el incremento observado en la sensibilización a este polen. Los síntomas predominantes son rinitis y conjuntivitis. El impacto clínico de esta alergia es pobre en áreas del sur de Italia, siendo alto en las áreas del norte (AU)


Asunto(s)
Humanos , Cupressus , Polen/efectos adversos , Rinitis Alérgica Estacional/epidemiología , Antígenos de Plantas/aislamiento & purificación , Anafilaxia/epidemiología , Italia , Pruebas Cutáneas , Encuestas Epidemiológicas
6.
Eur Ann Allergy Clin Immunol ; 37(1): 7-10, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15745370

RESUMEN

BACKGROUND: Eosinophil infiltration may be considered characteristic of nasal allergic inflammation. However, a mild inflammatory infiltrate may be present in asymptomatic subjects exposed to specific allergen. OBJECTIVE: We investigated the relationship between inflammation, specific hyperreactivity and clinical late phase reactions in allergic subjects using the ASNC model. METHODS: Sixty allergic subjects (aged from 18 to 47 years) were enrolled among those sensitized to pollens (n=20) and those to house dust mite with (n=20) or without (n=20) known clinical nasal LPR. All subjects were asymptomatic. TNSS and eosinophil number were assessed at baseline, 30 min (early phase) and 6 hours (late phase) after ASNC. RESULTS: Eosinophil number was higher in LPR+ rhinitics than in other groups, at baseline and during the early and late phase (p<0.001). ATD was lower in LPR+ rhinitics than in other groups (p<0.001). In LPR+ rhinitics, at baseline there was a significant correlation between eosinophils and ATD (r=0.56, p=0.009). After allergen challenge, TNSS was significantly higher in LPR+ rhinitics than in other groups, both during early and late phase (p<0.001 for all comparisons). CONCLUSIONS: In house dust mite sensitised subjects, LPR occurrence after allergen challenge is associated with higher inflammation and lower ATD at baseline. Therefore, in house dust mite allergy minimal persistent inflammation without symptoms can drive different clinical responses to allergen challenge.


Asunto(s)
Alérgenos , Eosinófilos/inmunología , Hipersensibilidad Tardía/inmunología , Rinitis Alérgica Perenne/inmunología , Rinitis Alérgica Estacional/inmunología , Adolescente , Adulto , Animales , Quimiotaxis de Leucocito , Femenino , Humanos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Ácaros/inmunología , Cavidad Nasal/inmunología , Cavidad Nasal/patología , Obstrucción Nasal/etiología , Polen/efectos adversos , Prurito/etiología , Estornudo
7.
Eur Ann Allergy Clin Immunol ; 36(6): 237-40, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15329007

RESUMEN

Cetirizine has been demonstrated able of reducing nasal inflammatory infiltration in children with allergic rhinitis and cytokine production in in vitro studies. The aim of this double-blind, placebo-controlled, and randomized study was to evaluate cytokine pattern and inflammatory cells in children with perennial allergic rhinitis, before and after treatment with cetirizine or placebo. Twenty children with perennial allergic rhinitis were evaluated, 13 males and 7 females (mean age 13.4 years). Inflammatory cells and cytokines were evaluated by scraping and nasal lavage, before and after 2-weeks administration of cetirizine or placebo. IL4 and IL8 were measured by immunoassay and inflammatory cells were counted by conventional staining. Cetirizine treatment induced a significant decrease of IL4 (p<0.01) and IL8 levels (p=0.01). A significant reduction of the inflammatory cells was detected in actively-treated children, both concerning neutrophils and eosinophils (p<0.01). Moreover, cetirizine significantly reduced nasal obstruction score (p=0.007). This study shows the cetirizine effectiveness in exerting anti-inflammatory activity by modulating cytokine pattern and by reducing inflammatory infiltration in children with perennial allergic rhinitis.


Asunto(s)
Cetirizina/uso terapéutico , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Interleucina-4/análisis , Interleucina-8/análisis , Mucosa Nasal/patología , Rinitis Alérgica Perenne/tratamiento farmacológico , Rinitis Alérgica Estacional/tratamiento farmacológico , Adolescente , Animales , Niño , Método Doble Ciego , Ensayo de Inmunoadsorción Enzimática , Eosinófilos/patología , Femenino , Humanos , Masculino , Líquido del Lavado Nasal/química , Mucosa Nasal/inmunología , Obstrucción Nasal/etiología , Neutrófilos/patología , Polen/inmunología , Estudios Prospectivos , Pyroglyphidae/inmunología , Rinitis Alérgica Perenne/complicaciones , Rinitis Alérgica Perenne/inmunología , Rinitis Alérgica Perenne/patología , Rinitis Alérgica Estacional/complicaciones , Rinitis Alérgica Estacional/inmunología , Rinitis Alérgica Estacional/patología , Resultado del Tratamiento
8.
Monaldi Arch Chest Dis ; 56(6): 508-13, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11980282

RESUMEN

To date the position of Leukotriene Receptor Antagonists (LTRAs) in asthma is not yet fully established. Recent asthma guidelines consider LTRAs as 'alternative' to low doses of inhaled corticosteroids (ICS) for treatment of patients with mild persistent asthma, while in Europe LTRAs are licensed as additional therapy to ICS. Our aim in this paper is to review comparative studies between ICS and antileukotrienes in mild to moderate asthma, looking at their efficacy on asthma outcomes and on patient expectations (compliance, quality of life, and safety). Some studies report a superior efficacy of ICS, while others, in particular in patients aged < 12 years, found no differences. When considering patients' expectations LTRAs seem to be superior, with higher compliance and quality of life. Even if no differences in adverse effects have been found between ICS and LTRAs, whose safety profiles are not different from placebo, some concerns exist on long term treatment with ICS, even at low doses, in children and postmenopausal women. For this reason, even if ICS are superior to LTRAs in controlling asthma outcomes and in improving pulmonary function, in children and elderly patients LTRAs can be considered an alternative to low-dose ICS.


Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Antagonistas de Leucotrieno/uso terapéutico , Corticoesteroides/uso terapéutico , Antiasmáticos/efectos adversos , Asma/patología , Humanos , Antagonistas de Leucotrieno/efectos adversos , Cooperación del Paciente , Calidad de Vida , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA